Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:PROK NASDAQ:TRVI NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$5.37-0.8%$5.45$4.41▼$8.69$2.01B0.421.96 million shs2.53 million shsPROKProKidney$1.83+1.1%$1.85$0.54▼$7.13$552.77M1.7897,612 shs1.00 million shsTRVITrevi Therapeutics$14.14-2.1%$13.41$5.38▼$16.12$2.01B1.071.47 million shs1.01 million shsTYRATyra Biosciences$33.41+2.2%$35.74$8.88▼$40.65$1.99B0.79935,272 shs1.08 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+0.67%-0.81%-4.64%-8.51%+19.14%PROKProKidney0.00%+3.43%-1.09%-19.20%+156.45%TRVITrevi Therapeutics0.00%+2.05%+4.60%+21.22%+130.83%TYRATyra Biosciences-1.48%-1.03%-6.79%-1.89%+263.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$5.37-0.8%$5.45$4.41▼$8.69$2.01B0.421.96 million shs2.53 million shsPROKProKidney$1.83+1.1%$1.85$0.54▼$7.13$552.77M1.7897,612 shs1.00 million shsTRVITrevi Therapeutics$14.14-2.1%$13.41$5.38▼$16.12$2.01B1.071.47 million shs1.01 million shsTYRATyra Biosciences$33.41+2.2%$35.74$8.88▼$40.65$1.99B0.79935,272 shs1.08 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+0.67%-0.81%-4.64%-8.51%+19.14%PROKProKidney0.00%+3.43%-1.09%-19.20%+156.45%TRVITrevi Therapeutics0.00%+2.05%+4.60%+21.22%+130.83%TYRATyra Biosciences-1.48%-1.03%-6.79%-1.89%+263.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.80Reduce$8.0049.11% UpsidePROKProKidney 2.50Moderate Buy$7.40304.37% UpsideTRVITrevi Therapeutics 3.00Buy$22.9061.95% UpsideTYRATyra Biosciences 2.85Moderate Buy$46.5039.18% UpsideCurrent Analyst Ratings BreakdownLatest PROK, TRVI, BHC, and TYRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026TRVITrevi Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.005/19/2026TYRATyra Biosciences Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform5/18/2026PROKProKidney HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/14/2026TYRATyra Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/8/2026TRVITrevi Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$30.005/6/2026TRVITrevi Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.005/6/2026TRVITrevi Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.005/6/2026TRVITrevi Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $23.005/4/2026BHCBausch Health Cos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/27/2026BHCBausch Health Cos Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$10.00 ➝ $9.004/21/2026PROKProKidney Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$10.27B0.20$7.25 per share0.74($2.89) per share-1.86PROKProKidney$890K621.09N/AN/A($3.39) per share-0.54TRVITrevi TherapeuticsN/AN/AN/AN/A$1.21 per shareN/ATYRATyra BiosciencesN/AN/AN/AN/A$6.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos$157M-$3.24N/A1.42N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)PROKProKidney-$68.99M-$0.53N/AN/AN/A-8,131.50%N/A-21.39%8/11/2026 (Estimated)TRVITrevi Therapeutics-$42.76M-$0.32N/AN/AN/AN/A-24.53%-23.37%8/6/2026 (Estimated)TYRATyra Biosciences-$119.95M-$2.18N/AN/AN/AN/A-42.66%-39.79%8/13/2026 (Estimated)Latest PROK, TRVI, BHC, and TYRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PROKProKidney-$0.13-$0.14-$0.01-$0.14$0.10 million$0.23 million5/13/2026Q1 2026TYRATyra Biosciences-$0.60-$0.64-$0.04-$0.64N/AN/A5/5/2026Q1 2026TRVITrevi Therapeutics-$0.07-$0.09-$0.02-$0.09N/AN/A4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billion3/18/2026Q4 2025PROKProKidney-$0.16-$0.14+$0.02-$0.13$0.00 million$0.23 million3/17/2026Q4 2025TRVITrevi Therapeutics-$0.10-$0.06+$0.04-$0.06N/AN/A3/2/2026Q4 2025TYRATyra Biosciences-$0.54-$0.57-$0.03-$0.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos54.681.320.97PROKProKidneyN/A9.069.06TRVITrevi TherapeuticsN/A24.7524.75TYRATyra BiosciencesN/A20.4920.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%PROKProKidney51.59%TRVITrevi Therapeutics95.76%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos20.67%PROKProKidney39.83%TRVITrevi Therapeutics18.30%TYRATyra Biosciences12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,300373.81 million296.55 millionOptionablePROKProKidney3302.06 million181.75 millionOptionableTRVITrevi Therapeutics20141.98 million116.00 millionOptionableTYRATyra Biosciences2059.47 million52.04 millionOptionablePROK, TRVI, BHC, and TYRA HeadlinesRecent News About These CompaniesTyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of "Moderate Buy" by AnalystsMay 22, 2026 | americanbankingnews.comTYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAYMay 21, 2026 | prnewswire.comWolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendationMay 20, 2026 | msn.comQ3 Earnings Estimate for TYRA Issued By HC WainwrightMay 18, 2026 | americanbankingnews.comTyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More SharesMay 17, 2026 | fool.comAssessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price MomentumMay 15, 2026 | finance.yahoo.comHot Picks: Cancer biotech stocks gain ground amid M&A activityMay 13, 2026 | bnnbloomberg.caBTyra Biosciences (NASDAQ:TYRA) Issues Quarterly Earnings ResultsMay 13, 2026 | marketbeat.comTyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comTyra Biosciences Reports First Quarter 2026 Financial Results and Recent HighlightsMay 13, 2026 | prnewswire.comTyra Biosciences to Participate in Upcoming Investor ConferencesMay 7, 2026 | prnewswire.comTyra Biosciences (TYRA) Expected to Announce Earnings on ThursdayMay 7, 2026 | marketbeat.comTyra Biosciences faces earnings test ahead of key trial dataApril 29, 2026 | investing.comTyra Bioscience, IncApril 25, 2026 | edition.cnn.comTyra Bioscience (TYRA) Receives a Buy from OppenheimerApril 25, 2026 | theglobeandmail.comGuggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug DabogratinibApril 24, 2026 | insidermonkey.comTyra Biosciences, Inc. ($TYRA) CEO 2025 Pay RevealedApril 17, 2026 | quiverquant.comQTyra Biosciences Announces Appointment of Habib Dable to its Board of DirectorsApril 17, 2026 | prnewswire.comGuggenheim initiates coverage of Tyra Biosciences (TYRA) with buy recommendationApril 16, 2026 | msn.comCanaccord Genuity initiates coverage of Tyra Biosciences (TYRA) with buy recommendationApril 7, 2026 | msn.comA Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial ProgressApril 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePROK, TRVI, BHC, and TYRA Company DescriptionsBausch Health Cos NYSE:BHC$5.36 -0.05 (-0.83%) Closing price 03:59 PM EasternExtended Trading$5.37 +0.00 (+0.09%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.ProKidney NASDAQ:PROK$1.83 +0.02 (+1.10%) Closing price 04:00 PM EasternExtended Trading$1.85 +0.02 (+1.15%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Trevi Therapeutics NASDAQ:TRVI$14.14 -0.31 (-2.15%) Closing price 04:00 PM EasternExtended Trading$14.06 -0.08 (-0.53%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.Tyra Biosciences NASDAQ:TYRA$33.41 +0.73 (+2.23%) Closing price 04:00 PM EasternExtended Trading$33.55 +0.14 (+0.42%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
